{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:59:00Z","timestamp":1781060340074,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00520-026-10833-5","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:00:20Z","timestamp":1779768020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac monitoring in adolescent and young adult cancer patients treated with anthracyclines: a longitudinal descriptive study"],"prefix":"10.1007","volume":"34","author":[{"given":"Jingwei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"10833_CR1","doi-asserted-by":"publisher","first-page":"i4567","DOI":"10.1136\/bmj.i4567","volume":"354","author":"SS Ahmad","year":"2016","unstructured":"Ahmad SS, Reinius MAV, Hatcher HM, Ajithkumar TV (2016) Anticancer chemotherapy in teenagers and young adults: managing long term side effects. BMJ 354:i4567","journal-title":"BMJ"},{"key":"10833_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1517\/14740338.5.6.791","volume":"5","author":"RL Jones","year":"2006","unstructured":"Jones RL, Swanton C, Ewer MS (2006) Anthracycline cardiotoxicity. Expert Opin Drug Saf 5:791\u2013809","journal-title":"Expert Opin Drug Saf"},{"key":"10833_CR3","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077\u20131084","journal-title":"N Engl J Med"},{"key":"10833_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","volume":"128","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions. Circulation 128:1927\u20131995","journal-title":"Circulation"},{"key":"10833_CR5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063\u20131093","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10833_CR6","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"10833_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35:893\u2013911","journal-title":"J Clin Oncol"},{"key":"10833_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31:171\u2013190","journal-title":"Ann Oncol"},{"key":"10833_CR9","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229\u20134361","journal-title":"Eur Heart J"},{"key":"10833_CR10","unstructured":"Japanese Society of Medical Oncology, Japanese Onco-Cardiology Society (eds)\u00a0(2023)\u00a0Onco-cardiology guidelines.\u00a0Nankodo [in Japanese]"},{"key":"10833_CR11","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s11764-020-00965-w","volume":"15","author":"HC Tanenbaum","year":"2021","unstructured":"Tanenbaum HC, Wolfson J, Xu L, Hahn EE, Bhatia S, Cannavale K et al (2021) Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and\/or anthracyclines. J Cancer Surviv 15:738\u2013747","journal-title":"J Cancer Surviv"},{"key":"10833_CR12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, Henriksen PA, Lenihan D, Dent S et al (2020) Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio\u2010Oncology Study Group of the Heart Failure Association and the Cardio\u2010Oncology Council of the European Society of Cardiology. Eur J Heart Fail 22:1966\u20131983","journal-title":"Eur J Heart Fail"},{"key":"10833_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T (2021) Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med 22:118\u2013127","journal-title":"J Gen Fam Med"},{"key":"10833_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2025.101090","volume":"46","author":"H Mamiya","year":"2025","unstructured":"Mamiya H, Fukasawa T, Kawakami K (2025) Effects of reimbursement add-on policies on trastuzumab and bevacizumab biosimilar adoption in a Japanese oncology setting. Value Health Reg Issues 46:101090","journal-title":"Value Health Reg Issues"},{"key":"10833_CR15","doi-asserted-by":"publisher","unstructured":"Nakao YM, Fukasawa T, Kawakami K (2026) From insurance records to epidemiology: Provenance and processing of Japanese claims data. Ann Clin Epidemiol [Internet]. Available from: https:\/\/doi.org\/10.37737\/ace.27004","DOI":"10.37737\/ace.27004"},{"key":"10833_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G (2004) A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159:702\u2013706","journal-title":"Am J Epidemiol"},{"key":"10833_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41416-020-1019-z","volume":"123","author":"S Conroy","year":"2020","unstructured":"Conroy S, Murray EJ (2020) Let the question determine the methods: descriptive epidemiology done right. Br J Cancer 123:1351\u20131352","journal-title":"Br J Cancer"},{"key":"10833_CR18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/aje\/kwac115","volume":"191","author":"CR Lesko","year":"2022","unstructured":"Lesko CR, Fox MP, Edwards JK (2022) A framework for descriptive epidemiology. Am J Epidemiol 191:2063\u20132070","journal-title":"Am J Epidemiol"},{"key":"10833_CR19","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/aje\/kwac056","volume":"191","author":"MP Fox","year":"2022","unstructured":"Fox MP, Murray EJ, Lesko CR, Sealy-Jefferson S (2022) On the need to revitalize descriptive epidemiology. Am J Epidemiol 191:1174\u20131179","journal-title":"Am J Epidemiol"},{"key":"10833_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s11764-017-0634-z","volume":"11","author":"KC Marr","year":"2017","unstructured":"Marr KC, Agha M, Sutradhar R, Pole JD, Hodgson D, Guttmann A et al (2017) Specialized survivor clinic attendance increases adherence to cardiomyopathy screening guidelines in adult survivors of childhood cancer. J Cancer Surviv 11:614\u2013623","journal-title":"J Cancer Surviv"},{"key":"10833_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cam4.4929","volume":"12","author":"T Ishii","year":"2023","unstructured":"Ishii T, Watanabe T, Higashi T (2023) Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines. Cancer Med 12:122\u2013130","journal-title":"Cancer Med"},{"key":"10833_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaccao.2024.11.003","volume":"7","author":"VU Rao","year":"2025","unstructured":"Rao VU, Deswal A, Lenihan D, Dent S, Lopez-Fernandez T, Lyon AR et al (2025) Quality-of-care measures for cardio-oncology: an IC-OS and ACC cardio-oncology leadership council perspective. JACC CardioOncol 7:191\u2013202","journal-title":"JACC CardioOncol"},{"key":"10833_CR23","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1200\/JCO.2014.58.9465","volume":"33","author":"M Chavez-MacGregor","year":"2015","unstructured":"Chavez-MacGregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J et al (2015) Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. J Clin Oncol 33:2176\u20132183","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10833-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:29:11Z","timestamp":1781058551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10833-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10833"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10833-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (No. R3380).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As the data were anonymized, informed consent was not required in accordance with Japanese ethical guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Toshiki Fukasawa was previously employed by the Department of Digital Health and Epidemiology at Kyoto University with support from Eisai Co., Ltd. and Kyowa Kirin Co., Ltd.; he has received research funding from AstraZeneca K.K. and the Pfizer Health Research Foundation, consulting fees from Asahi Kasei Pharma Corporation, JMDC Inc., and MSD K.K., and honoraria from DeSC Healthcare, Inc. and the Research Institute of Healthcare Data Science. Masato Takeuchi has received consulting fees from Eisai Co., Ltd. Koji Kawakami receives research funding from AstraZeneca K.K., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., OMRON Corporation, and Toppan Inc.; consulting fees from Advanced Medical Care Inc., JMDC Inc., Shin Nippon Biomedical Laboratories Ltd., and Ubicom Holdings, Inc.; executive compensation from Cancer Intelligence Care Systems, Inc. and Mytreya Inc.; and honoraria from Pharma Business Academy Co., Ltd. and SANSHO Co., Ltd. The other authors have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"579"}}